These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 28106149)

  • 1. Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME.
    Sarafidis PA; Lazaridis AA; Ruiz-Hurtado G; Ruilope LM
    Nat Rev Endocrinol; 2017 Jun; 13(6):365-374. PubMed ID: 28106149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The optimal blood pressure target in diabetes mellitus: a quest coming to an end?
    Papadopoulou E; Angeloudi E; Karras S; Sarafidis P
    J Hum Hypertens; 2018 Oct; 32(10):641-650. PubMed ID: 29934621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Hypertension: Which Goal for Which Patient?
    Jarraya F
    Adv Exp Med Biol; 2017; 956():117-127. PubMed ID: 27722961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2017 May; 35(5):922-944. PubMed ID: 28141660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical benefit of systolic blood pressure within the target range among patients with or without diabetes mellitus: a propensity score-matched analysis of two randomized clinical trials.
    Li C; Chen K; Shi G; Shi R; Wu Z; Yuan X; Watson V; Jiang Z; Mai H; Yang T; Wang D; Chen T
    BMC Med; 2022 Jun; 20(1):208. PubMed ID: 35718771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
    Ferreira JP; Fitchett D; Ofstad AP; Kraus BJ; Wanner C; Zwiener I; Zinman B; Lauer S; George JT; Rossignol P; Zannad F
    Am J Hypertens; 2020 Dec; 33(12):1092-1101. PubMed ID: 32369546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood pressure targets for hypertension in people with diabetes mellitus.
    Arguedas JA; Leiva V; Wright JM
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD008277. PubMed ID: 24170669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT.
    Beddhu S; Chertow GM; Greene T; Whelton PK; Ambrosius WT; Cheung AK; Cutler J; Fine L; Boucher R; Wei G; Zhang C; Kramer H; Bress AP; Kimmel PL; Oparil S; Lewis CE; Rahman M; Cushman WC
    J Am Heart Assoc; 2018 Sep; 7(18):e009326. PubMed ID: 30371182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting blood pressure in people with diabetes mellitus.
    Brimble KS
    Pol Arch Med Wewn; 2016 Jun; 126(6):411-8. PubMed ID: 27362394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive Blood Pressure Lowering in Patients With and Patients Without Type 2 Diabetes: A Pooled Analysis From Two Randomized Trials.
    Brouwer TF; Vehmeijer JT; Kalkman DN; Berger WR; van den Born BH; Peters RJ; Knops RE
    Diabetes Care; 2018 Jun; 41(6):1142-1148. PubMed ID: 29212825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.
    Scheen AJ
    Diabetes Res Clin Pract; 2016 Nov; 121():204-214. PubMed ID: 27744129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension.
    Chilton R; Tikkanen I; Hehnke U; Woerle HJ; Johansen OE
    Diabetes Obes Metab; 2017 Nov; 19(11):1620-1624. PubMed ID: 28387058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 13 - benefits and adverse events in older and younger patients with hypertension: overview, meta-analyses and meta-regression analyses of randomized trials.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2018 Aug; 36(8):1622-1636. PubMed ID: 29847485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication.
    Mancia G; Cannon CP; Tikkanen I; Zeller C; Ley L; Woerle HJ; Broedl UC; Johansen OE
    Hypertension; 2016 Dec; 68(6):1355-1364. PubMed ID: 27977392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
    Chilton R; Tikkanen I; Cannon CP; Crowe S; Woerle HJ; Broedl UC; Johansen OE
    Diabetes Obes Metab; 2015 Dec; 17(12):1180-93. PubMed ID: 26343814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Target Blood Pressure in Patients with Diabetes: Asian Perspective.
    Park S; Kario K; Park CG; Huang QF; Cheng HM; Hoshide S; Wang JG; Chen CH;
    Yonsei Med J; 2016 Nov; 57(6):1307-11. PubMed ID: 27593856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials.
    Liu J; Pong A; Gallo S; Darekar A; Terra SG
    Cardiovasc Diabetol; 2019 May; 18(1):59. PubMed ID: 31064361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EMPA-REG OUTCOME: The Endocrinologist's Point of View.
    Perreault L
    Am J Med; 2017 Jun; 130(6S):S51-S56. PubMed ID: 28526185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics.
    Scheen AJ
    Diabetes Metab; 2016 Sep; 42(4):224-33. PubMed ID: 27291329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.